BLS Pharmaceuticals Limited (ASX: BLS), an Australian pharmaceutical company focused on the manufacture, development and commercialisation of regulated therapeutic products and active pharmaceutical ingredients, has announced its full year FY2027 guidance. The company, which operates a GMP-licensed manufacturing, import, export and distribution platform spanning medicinal cannabis, psychedelic medicines and other controlled pharmaceutical products, is targeting revenue of $105 million to $115 million for FY2027. This projection represents an anticipated growth of 42% to 55% over its FY2026 revenue of $74.2 million. BLS also provided an Adjusted EBITDA margin guidance of 23% to 26% for the same period.
The robust outlook for FY2027 is underpinned by several strategic pillars. BLS expects continued strong demand within Australia, where it possesses significant available manufacturing capacity across its GMP-licensed pharmaceutical operations. Internationally, the company will benefit from the execution of existing contracts, notably its two-year A$50 million supply agreement with ADREXpharma in Germany. Furthermore, a new GMP production site is currently under construction in the Scottish Borders, United Kingdom, with completion expected by the end of 2026, which will bolster manufacturing capacity and facilitate access to UK and broader international markets.
BLS Pharmaceuticals highlighted a favourable and evolving global regulatory environment, with increasing acceptance of cannabis, MDMA, and psilocybin-based medicines supporting the markets it serves. The company has also established commercial relationships across Europe and Latin America and secured manufacturing agreements with industry leaders such as Aurora Cannabis and Curaleaf International. Sam Watson, BLS Managing Director and Founder, commented, “We enter FY27 with more manufacturing capacity, better market access, bigger contracts and more opportunities than ever before. Our focus in FY27 is on execution and delivering sustained, long-term value for our shareholders.”
